Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma

There is a need for updated studies regarding the efficacy of single-agent chemotherapy for Black patients with cutaneous T-cell lymphoma. This study evaluates outcomes of single-agent chemotherapy for cutaneous T-cell lymphoma in a large and diverse cohort of patients. Both gemcitabine and pegylated liposomal doxorubicin had promising response rates and time to next treatment, including in Black patients with recalcitrant cutaneous T-cell lymphoma.